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As of March 30th, 2020 there were 161,807 total cases and 2,953 total deaths of SARS-CoV-2 in 
the United States, with the number of cases expected to rise. Other than supportive care, there 
are no SARS-CoV-2 specific treatments available for patients discharged from the emergency 
department (ED) or those admitted to the hospital. In addition, there are no vaccines available 
to protect our at-risk healthcare workers. The National Institutes of Health is conducting a Phase 
1 clinical trial to evaluate for a potential vaccine and the recipients have started to receive the 
investigational vaccine.2 We present a brief overview of the potential prophylactic and treatment 
agents under investigation, some which could be initiated in the ED if proven effective. [West J 
Emerg Med. 2020;21(3)X–X.]
Disclaimer: Due to the rapidly evolving nature of this outbreak, 
and in the interests of rapid dissemination of reliable, actionable 
information, this paper went through expedited peer review. 
Additionally, information should be considered current only at 
the time of publication and may evolve as the science develops. 
INTRODUCTION
As of March 30th, 2020 there were 161,807 total cases and 
2,953 total deaths of SARS-CoV-2 in the United States,1 with 
the number of cases expected to rise. Other than supportive 
care, there are no SARS-CoV-2 specific treatments available 
for patients discharged from the emergency department (ED) 
or those admitted to the hospital. In addition, there are no 
vaccines available to protect our at-risk healthcare workers. The 
National Institutes of Health is conducting a Phase 1 clinical 
trial to evaluate for a potential vaccine.2 We present a brief 
overview of the potential prophylactic and treatment agents 
under investigation, some of which could be initiated in the ED 
if proven effective.  
METHODS
We conducted a literature search on March 17th, 2020 
(updated March 30th, 2020) on PubMed and the Cochrane 
Library. Search terms included “COVID-19/SARS-CoV-2 
treatment or prophylaxis or drugs or therapy.” Abstracts of 
relevant papers were reviewed by the authors. Drug information 
was obtained from Lexicomp Online.3
CONVALESCENT SERUM
Human convalescent sera has been used since the early 
twentieth century and is currently under investigation for 
prophylaxis and treatment.4 To obtain the serum, blood is drawn 
from a subject who has recently recovered from the target 
disease. After processing, blood that is noted to have high titers 
of neutralizing antibodies is then administered to high risk 
individuals such as those with underlying medical conditions, 
healthcare providers, or those with confirmed exposure. 
Convalescent sera has also been used in modern times. 
It was used during the H1N1 influenza outbreak and found to 
reduce respiratory viral burden, cytokine response, and mortality 
in H1N1 infected ICU patients.5 Convalescent sera has also 
been used for other coronaviruses. Eighty SARS-CoV positive 
patients treated with convalescent serum before day 14 of illness 
had improved prognosis compared to those treated later.6 There 
are case reports of convalescent sera administration during the 
current SARS-CoV-2 outbreak in China, but few details are 
available.7 In addition, the drug maker Takeda is working on 
developing a SARS-CoV-2  immunoglobulin serum.4 
To enter a cell, coronaviruses depend on the binding of the 
viral spike proteins to cellular receptors as well as S protein 
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What do we already know about this issue?
There are now over  150,000 individuals, 
worldwide, with COVID-19, the disease 
caused by the SARS-CoV-2 virus.
What was the research question?
This paper summarizes the literature on 
potential prophylactic and treatment drugs in 
consideration for COVID-19.
What was the major finding of the study?
There is limited data supporting all potential 
COVID-19 treatment and prophylactic drugs 
but some show promise.
How does this improve population health?
A potential treatment or prophylactic drug for 
COVID-19 could halt the course of the current 
pandemic and save lives. 
priming by host cell proteases. Hoffmann et al found that 
SARS-CoV-2 uses the SARS-CoV angiotensin converting 
enzyme 2 (ACE2) receptor to enter cells and the serine 
protease TMPRSS2 for S protein priming.8 Hoffmann et al 
utilized this information and found that convalescent SARS-
CoV serum, which is known to have a neutralizing antibody 
against the viral S protein, decreased SARS-CoV-2 entry 
into the cell in vitro. They also found that rabbit serum raised 
against the S1 subunit of the SARS-CoV virus inhibited 
SARS-CoV and SARS-CoV-2 entry into the cell in vitro. 
These data suggest that neutralizing antibody responses raised 
against SARS-CoV might offer protection against SARS-
CoV-2. In addition, given that TMPRSS2 is required for entry, 
a TMPRSS2 inhibitor, although not convalescent serum, is 
another possible target. 
There are, however, known risks of convalescent sera 
including possible allergic reaction to other products in the sera 
and transmission of other diseases. There are also theoretical 
risks, most notably antibody-dependent enhancement of 
infection as well as the possibility that antibody exposure may 
attenuate the immune system leaving individuals vulnerable to 
subsequent reinfection.9 
The feasibility of extracting, processing, and providing the 
serum to ED clinicians for use is a challenge. A commercially 
available product could be easier to procure and administer. 
However, at this time there is no formal recommendation or 
guidelines to initiate this therapy for patients in the ED or 
those clinicians working directly with COVID-19 patients. 
OTHER POSSIBLE PROPHYLACTIC OR 
TREATMENT AGENTS
SARS-CoV, MERS-CoV, and SARS-CoV-2 are all 
betacoronaviruses. Although no prophylaxis or treatment 
exists against SARS-CoV-2, there are several drugs which 
have been subject to limited trials or are currently under 
investigation.10 These drugs include remdesivir, chloroquine, 
hydroxychloroquine, azithromycin, lopinavir-ritonavir, 
tocilizumab, sarilumab, and losartan. 
Both remdesivir and chloroquine have shown some 
efficacy against SARS-CoV-2. Remdesivir incorporates into 
nascent viral RNA chains causing pre-mature termination 
whereas chloroquine increases the endosomal pH required for 
viral/cell fusion and interferes with glycosylation of cellular 
receptors. 
Wang et al showed that remdesivir and chloroquine had 
a high selectivity against SARS-CoV-2 and blocked viral 
infection in vitro in African green monkey cells.11 Remdesivir 
interfered after the virus had entered the cell, whereas 
chloroquine interfered at entry and post-entry stages. More 
importantly, their preliminary data suggest the same effects in 
human cell lines.
In the U.S., remdesivir is currently only available as an 
investigational agent or through compassionate use protocols 
for confirmed SARS-CoV-2 hospitalized patients with 
invasive mechanical ventilation.12 At this time, the use of this 
agent in the ED is unlikely. 
Chloroquine and hydroxychloroquine are oral medications 
that could potentially be used to treat outpatients and those 
admitted to the hospital. However, as with this author’s 
institution, these agents may be restricted for COVID-19 
indications in the ED until further evidence is available 
with several exceptions including very sick patients that are 
admitted. As these agents are available in the community, 
ED clinicians should exercise caution counseling patients 
inquiring about chloroquine and hydroxychloroquine, 
especially with the recent report of a fatal chloroquine 
overdose intended for COVID-19 self-treatment.13 
There are currently over 10 clinical trials in China 
evaluating the effect and safety of chloroquine in the treatment 
of SARS-CoV-2 associated pneumonia. Although preliminary 
data have not been released, Gao et al reported in a  news 
briefing  by the State Council of China  that chloroquine 
phosphate had “demonstrated marked efficacy and acceptable 
safety in treating COVID-19 associated pneumonia in 
multicenter clinical trials.”14,15 
Hydroxychloroquine is a chloroquine analog with 
fewer drug-drug interactions. Yao et al studied African 
green monkey cells in vitro and found that chloroquine 
and hydroxychloroquine decreased SARS-CoV-2 viral 
replication in a concentration-dependent manner but that 
hydroxychloroquine was more potent.16 They also evaluated 
physiologically-based pharmacokinetic models in vivo. Based 
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on these results, they recommend an oral loading dose of 
400 mg hydroxychloroquine sulfate twice daily on day one 
followed by a maintenance dose of 200 mg twice daily for 
four days. 
Jun et al conducted a prospective study of 30 SARS-
CoV-2 positive patients randomized to either standard 
treatment or hydroxychloroquine. They found no difference 
between the two groups with respect to median duration from 
hospitalization to undetectable serum SARS-CoV-2, median 
time to body temperature normalization, and development 
of diarrhea and liver function test abnormalities.17 Gautret 
et al, however, found that the addition of azithromycin to 
hydroxychloroquine improved virus elimination.18 There are 
current studies investigating the use of hydroxychloroquine 
chemoprophylaxis for healthcare workers (ClinicalTrials.gov: 
NCT04318015).
Cao et al conducted a randomized, controlled, open label 
trial of lopinavir-ritonavir with 199 SARS-CoV-2 hospitalized 
adult patients with an oxygen saturation less than or equal to 
94% on room air or partial pressure of oxygen to fraction of 
inspired oxygen less than 300 This cohort would then include 
mild, moderate as well as severely hypoxic patients.19 They 
found no difference in 28 day mortality in the lopinavir-
ritonavir group compared to the standard-care group (19.2% 
vs 25.0%; 95% confidence interval [CI] -17.3 to 5.7) or 
percentages of patients with detectable viral RNA at various 
time points. They also noted significant gastrointestinal side 
effects and stopped the lopinavir-ritonavir early in 13 patients 
(13.8%) because of adverse events. The lack of survival 
benefit as well as the significant side effects make this drug 
unlikely to be used in the ED at this point. 
There are also ongoing studies with monoclonal 
antibodies tocilizumab (ClinicalTrials.gov: NCT04317092) 
and sarilumab (ClinicalTrials.gov: NCT04315298). Both of 
these agents are interleukin -6 receptor antagonists that could 
theoretically attenuate cytokine and acute phase reactants.3  
Further, as the SARS-CoV-2 depends on the ACE2 receptor 
for entry, another multicenter placebo-controlled trial is 
enrolling patients evaluating losartan (angiotensin 2 receptor 
blocker) in patients requiring hospitalizations (ClinicalTrials.
gov: NCT04312009).
SUMMARY
Convalescent sera has been used in the past as viral 
prophylaxis and treatment but there is currently a lack of 
human data on use against SARS-CoV-2. Remdesivir and 
chloroquine (or hydroxychloroquine) are two medications 
that have also shown promising results in vitro but clinical 
trial data have yet to be released. Press releases on these 
medications have discussed promising results. At this time 
there is no evidence or consensus to initiate these therapies 
in the ED. 
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